{"nctId":"NCT02436096","briefTitle":"A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia","startDateStruct":{"date":"2015-04"},"conditions":["Fibromyalgia","Myofascial Pain Syndromes","Muscular Diseases","Musculoskeletal Diseases","Nervous System Diseases","Neuromuscular Diseases","Rheumatic Diseases"],"count":519,"armGroups":[{"label":"TNX-102 SL Tablet, 2.8 mg","type":"EXPERIMENTAL","interventionNames":["Drug: TNX-102 SL Tablet, 2.8mg"]},{"label":"Placebo SL Tablet","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo SL Tablet"]}],"interventions":[{"name":"TNX-102 SL Tablet, 2.8mg","otherNames":["Low dose cyclobenzaprine sublingual tablets"]},{"name":"Placebo SL Tablet","otherNames":["Placebo sublingual tablets"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Primary Fibromyalgia (2010 ACR criteria)\n* Male or female 18-75 years old\n* For patients with major depressive disorders only: clinically stable, no suicidal risk and stable anti-depressant therapy\n* Willing and able to withdraw specific therapies (ask PI)\n* Medically acceptable form of contraception (female only)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Arthritis, lupus and other systemic auto-immune diseases\n* Regional or persistent pain that could interfere with assessment of fibromyalgia pain\n* Bipolar and psychotic disorders\n* Increased risk of suicide\n* Significant clinical (cardiac, systemic infection, systemic corticosteroid requirement, drug/alcohol abuse) or laboratory abnormalities.\n* Inability to wash-out specific medications (ask PI)\n* Known hypersensitivity to cyclobenzaprine\n* Others: seizure disorders, severe/untreated sleep apnea, BMI\\>40","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients With ≥30% Pain Improvement","description":"The primary efficacy endpoint is the proportion of patients with a ≥30% improvement (responder criteria) from baseline to Week 12 in the weekly mean of the daily self-reported 24-hour recall average pain intensity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Global Impression of Change (PGIC)","description":"Proportion of patients with a PGIC rating of 1 (\"very much improved\") or 2 (\"much improved\") at Week 12. The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates the highest level of worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score","description":"The FIQR is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.2","spread":"1.13"},{"groupId":"OG001","value":"-14.1","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 in the FIQR Function Domain Score","description":"The FIQR is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"1.15"},{"groupId":"OG001","value":"-10.3","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Patient Reported Outcomes Measurement System (PROMIS) Sleep Disturbance","description":"Change from baseline in the PROMIS score for sleep disturbance at Week 12. The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10. Lower T-scores indicate less sleep disturbance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":".53"},{"groupId":"OG001","value":"-8.0","spread":".54"}]}]}]},{"type":"SECONDARY","title":"Weekly Average of Daily Sleep Quality Diary","description":"Change from Baseline in the weekly average of the daily diary assessment of sleep quality at Week 12. Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.11"},{"groupId":"OG001","value":"-1.8","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Patient Reported Outcomes Measurement System (PROMIS) Fatigue","description":"Change from Baseline in the PROMIS score for fatigue at Week 12. The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10. Lower T-scores indicate less fatigue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":".47"},{"groupId":"OG001","value":"-6.4","spread":".47"}]}]}]},{"type":"SECONDARY","title":"Weekly Average of Daily Pain Diary","description":"Change from baseline to Week 12 in the weekly average of the daily self-reported average pain severity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.11"},{"groupId":"OG001","value":"-1.5","spread":"0.11"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":256},"commonTop":["Hypoaesthesia Oral","Glossodynia","Paraesthesia Oral","Fatigue","Product Taste Abnormal"]}}}